arrow_back Back to App

Enhanced Safety for Cell and Tissue Transplants: New Rules and Penalties.

This Act aims to improve the safety of human cell and tissue transplants by launching a national education campaign for patients and doctors about potential risks, including infection transmission. It also introduces significant financial penalties for companies that violate safety regulations regarding these products. Citizens will benefit from better information and increased confidence in the quality and safety of medical procedures.
Key points
Mandatory national campaign to educate the public and healthcare providers on the risks and benefits of human cell and tissue transplants.
Imposition of high civil penalties (up to $10 million) for establishments violating safety rules for cell and tissue products.
Requirement for the FDA to review and update guidelines for screening cell and tissue donors to enhance product safety.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_3733
Sponsor: Sen. Peters, Gary C. [D-MI]
Process start date: 2024-02-05
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Shandra Eisenga Human Cell and Tissue Product Safety Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_3733.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-02-05.

What are the main provisions?

Key points include:

  • Mandatory national campaign to educate the public and healthcare providers on the risks and benefits of human cell and tissue transplants.
  • Imposition of high civil penalties (up to $10 million) for establishments violating safety rules for cell and tissue products.
  • Requirement for the FDA to review and update guidelines for screening cell and tissue donors to enhance product safety.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Peters, Gary C. [D-MI].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health